Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
Celon Pharma SA (CLN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.013x
Based on the latest financial reports, Celon Pharma SA (CLN) has a cash flow conversion efficiency ratio of -0.013x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.88 Million) by net assets (zł389.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Celon Pharma SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Celon Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Celon Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celon Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
-0.187x |
|
AS Merko Ehitus
F:MKS
|
0.041x |
|
Jtekt India Limited
NSE:JTEKTINDIA
|
0.020x |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
0.091x |
|
Anhui Yuanchen Environmental Protection Science & Technology Co. Ltd.
SHG:688659
|
0.059x |
|
WALLIX GROUP EO -10
F:3WG
|
N/A |
|
Guararapes Confecções S.A
SA:GUAR3
|
0.055x |
|
West Shanghai Automotive Service Co.Ltd.
SHG:605151
|
0.058x |
Annual Cash Flow Conversion Efficiency for Celon Pharma SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of Celon Pharma SA from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł445.21 Million | zł-11.34 Million | -0.025x | -36.49% |
| 2023-12-31 | zł445.56 Million | zł-8.31 Million | -0.019x | -90.39% |
| 2022-12-31 | zł479.65 Million | zł-4.70 Million | -0.010x | -112.35% |
| 2021-12-31 | zł554.00 Million | zł43.95 Million | 0.079x | -51.36% |
| 2020-12-31 | zł434.67 Million | zł70.90 Million | 0.163x | +1537.33% |
| 2019-12-31 | zł445.04 Million | zł-5.05 Million | -0.011x | -118.03% |
| 2018-12-31 | zł448.73 Million | zł28.24 Million | 0.063x | +9.40% |
| 2017-12-31 | zł439.85 Million | zł25.30 Million | 0.058x | +12.15% |
| 2016-12-31 | zł402.50 Million | zł20.65 Million | 0.051x | -90.13% |
| 2015-12-31 | zł100.82 Million | zł52.37 Million | 0.519x | +48.46% |
| 2014-12-31 | zł69.62 Million | zł24.36 Million | 0.350x | +116.14% |
| 2013-12-31 | zł52.20 Million | zł8.45 Million | 0.162x | -30.09% |
| 2012-12-31 | zł55.57 Million | zł12.87 Million | 0.232x | -- |